Related Experiment Video
Updated: Sep 9, 2025
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
PopPK modeling supports BW band dosing of lacosamide for pediatric epilepsy
Yue Li1, Hong-Li Guo1, Lin Fan1
1Pharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
Insights
Simplified dosing for lacosamide (LCM) in children with epilepsy is now possible. Population pharmacokinetic modeling shows body weight bands or fixed doses achieve similar results to weight-based dosing, improving personalized treatment.
Area of Science:
- Pharmacology
- Pediatric Epilepsy
- Clinical Pharmacy
Background:
- Personalized precision dosing for antiepileptic drugs is a significant clinical challenge.
- Lacosamide (LCM) dosing in pediatric epilepsy often relies on body weight (BW)-based (mg/kg) regimens.
- Optimizing LCM dosing regimens can improve therapeutic outcomes and patient management.
Purpose of the Study:
- To evaluate the transition of lacosamide (LCM) dosing in pediatric epilepsy from body weight (BW)-based (mg/kg) to simplified BW-band or fixed-dose (mg) regimens.
- To assess the predictive performance of a genotype-guided dosing model compared to a BW-based model.
- To confirm comparable LCM exposure and target attainment across different dosing strategies.
Main Methods:
- Population pharmacokinetic (PopPK) modeling using nonlinear mixed-effects modeling on real-world data from 190 pediatric epilepsy patients.
- Comparison of a standard BW-based model (Model I) with a genotype-guided model (Model II).
- Monte Carlo simulations to evaluate LCM exposure and target attainment across various dosing regimens, including BW-band and fixed-dose strategies.
Main Results:
- The genotype-guided model (Model II) demonstrated superior predictive performance.
- Monte Carlo simulations confirmed comparable lacosamide (LCM) exposure across different dosing regimens.
- >78% target attainment was achieved in external validation.
- A fixed 100 mg dose for patients ≥10 kg showed equivalent exposure to BW-adjusted dosing, consistent across age groups (1-4 years) and obese patients.
Conclusions:
- Body weight (BW)-band dosing is a clinically viable and simplified alternative to mg/kg regimens for lacosamide (LCM) in pediatric epilepsy.
- CYP2C19 genotyping further enhances dosing precision, supporting personalized epilepsy management.
- This population pharmacokinetic (PopPK)-based strategy simplifies LCM therapy without compromising efficacy, offering a practical approach to pediatric epilepsy care.
Abstract:
Personalized precision dosing remains an unmet clinical need. This study used population pharmacokinetic (PopPK) modeling to evaluate transitioning lacosamide (LCM) in children with epilepsy from body weight (BW)-based (mg/kg) to simplified BW-band or fixed-dose (mg) regimens. Real-world data from 190 patients were analyzed using nonlinear mixed-effects modeling program, comparing a BW-based model (Model I) and a genotype-guided model (Model II); the latter showed superior predictive performance. Monte Carlo simulations confirmed comparable LCM exposure across regimens, with >78% target attainment in external validation. A fixed 100 mg dose for patients ≥10 kg achieved equivalent exposure to BW-adjusted dosing, with consistent results in 1-4 years and obese patients. These findings enabled BW-band dosing as a clinically viable alternative to mg/kg regimens, while CYP2C19 genotyping further enhanced precision. This PopPK-based strategy simplifies LCM therapy without compromising efficacy, offering a practical approach to personalized epilepsy management in children.
More Related Videos
10:46Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
Published on: September 1, 2023
06:30Author Spotlight: Advancing Genetic Epilepsy Studies with Multi-Electrode Array-Based Long-Term Electrophysiological Monitoring of Human Brain Assembloids
Published on: September 27, 2024
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...